Diabetes Obes Metab: Uric acid predicts long-term cardiovascular risk in people with type 2 diabetes

Non-Nobert can reduce long-term cardiovascular events, and the biomediate factors of its mechanism of action have not yet been fully identifiedA recent study in the journal Diabetes Obesity and Metabolism, an authoritative journal for metabolic endocrine diseases, aims to determine whether non-Nobert's heart protection is partly achieved through its role in reducing uric acid (UA)researchers used data from the Non-Norbert Intervention and Reduction of Diabetes Events (FIELD) trial, which included 9,795 adults with type 2 diabetes (T2D), randomly assigned to non-Nobert or matched placebo therapyThe researchers measured plasma UA levels before and after a six-week non-Nobert treatment for all participantsThe Cox Proportional Risk Model was used to explore the relationship between baseline UA levels, uA reductions before and after treatment, and long-term cardiovascular outcomessubjects had an average baseline baseline plasma UA of 0.33mmol/L (SD 0.08)Baseline UA levels are an important predictor of long-term cardiovascular events, with an increase of 21% for each increase of 0.1mmol/L (HR 1.21, 95% CI 1.13-1.29, p 0.001)After adjusting treatment distribution, cardiovascular risk factors and kidney function, the results were still significantThe degree of decrease in UA during non-Nobert treatment is also an important predictor of long-term cardiovascular events, with a 14% reduction in long-term risk for each increase of 0.1mmol/L (HR of 0.86, 95% CI for 0.76-0.97, p-0.015)The therapeutic grouping did not change this effect (interaction p.77)it can be seen that UA is a strong independent predictor of long-term cardiovascular risk in T2D patientsAlthough a largereduction reduction of UA by non-Nobert is a predictor of lower cardiovascular risk, this does not seem to mediate non-Nobert's heart protection